Hollander David 4
4 · KIORA PHARMACEUTICALS INC · Filed Feb 3, 2022
Insider Transaction Report
Form 4
Hollander David
Director
Transactions
- Award
Stock Option (right to buy)
2022-02-01+4,000→ 4,000 totalExercise: $0.77Exp: 2032-02-01→ Common Stock (4,000 underlying) - Award
Stock Option (right to buy)
2022-02-01+5,000→ 5,000 totalExercise: $0.77Exp: 2032-02-01→ Common Stock (5,000 underlying)
Footnotes (2)
- [F1]The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan in connection with the Reporting Person's appointment to the Issuer's Board of Directors. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.
- [F2]The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023.